Quetzal Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for QTX-2101, an oral arsenic trioxide capsule under development for acute promyelocytic leukemia (APL). The company focuses on creating therapies for rare diseases.
The Fast Track status is intended to expedite the review process for QTX-2101, potentially allowing faster access to this treatment for patients with APL.
**Why this matters**
Acute promyelocytic leukemia is a rare and aggressive form of leukemia requiring effective treatment options. The FDA’s Fast Track designation can facilitate the development and review of promising therapies, which may improve outcomes for patients facing this serious condition.